DMPE is the dimyristoylphosphatidylcholine. DMPE is a liposome used to deliver drugs.

Tyrosinase/elastase-IN-1 a triterpenoid from Rubus fraxinifolius leaves, has tyrosinase and elastase inhibitory activities.

Eupenifeldin is pentacyclic bistropolone isolated from cultures of Eupenicillium brefeldianum ATCC 74184. Eupenifeldin is cytotoxic against the HCT-116 cell line. Eupenifeldin has the potential for the research of leukemia.

BRD4 D1-IN-2 (compound 26) is a potent and selective BRD4 D1 inhibitor (IC50<0.092 µM). BRD4 D1-IN-2 has 15 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC.

KRAS G12C inhibitor 20 is a KRAS G12C inhibitor extracted from patent CN112694475A, example 1.

KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1).

photoCORM-1 (compound 8) is a combinatorial carbon monoxide releasing molecule (CORM). photoCORM-1 exhibits good cellular uptake and real-time monitoring ability of CO uncaging by a color change approach. photoCORM-1 has anti-tumor antivity.

Acremonidin A is a potent calmodulin (CaM) inhibitor found in Purpureocillium lilacinum. Acremonidin A binds to the human calmodulin (hCaM) biosensor hCaM M124C-mBBr, with Kd of 19.40 nM.

Acremoxanthone C is a potent calmodulin (CaM) inhibitor found in Purpureocillium lilacinum. Acremoxanthone C binds to the human calmodulin (hCaM) biosensor hCaM M124C-mBBr, with Kd of 18.25 nM.

Acid-PEG12-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Biotin-PEG10-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Rhamnolipid RL2, is a rhamnolipid, shows antifungal activity.

Homodestcardin, a destruxinbased cyclodepsipeptide, is a immunosuppressant. Homodestcardin, a fungal metabolite, displays pronounced activities against concanavalin A (Con A) activation, with an IC50 value of 0.86 μM.

Mal-Deferoxamine is the linker for construct RDC.

KRAS G12C inhibitor 22 is a KRAS G12C inhibitor extracted from patent WO2021219072A1, example 120.

KRAS G12C inhibitor 25 is a KRAS G12C inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC50=0.48 nM). From WO2021216770A1 compound 3.

Cytoglobosin C, a cytochalasan derivative, shows potent cytotoxicity against both SGC-7901 and A549 cell lines (IC50<10 μM).

Cytoglobosin D, a cytochalasan derivative, displays cytotoxic activity toward the A-549 cell line (IC50=2.55 μM).

BRD4 D1-IN-1 is a selective BRD4 D1 inhibitor (IC50<0.092 µM). BRD4 D1-IN-1 has 18 nM affinity against BRD4 D1 and over 500-fold selectivity against BRD2 D1 and BRD4 D2 via ITC.

SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM).

KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC50 of 491 nM (WO2021218939A1, compound 1).

GLP-1 receptor agonist 9 is a GLP-1 receptor agonist, example 7, extracted from WO2020234726 A1.

AChE-IN-4 shows the acetylcholine esterase inhibition (AChEI) with an IC50 value of 24.1 μM.

11-Keto fusidic acid shows strong antibacterial activity toward Staphylococcus aureus with an MIC value of 0.078 μg/mL.

Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively.

HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) .

Toddacoumalone is a natural inhibitor of phosphodiesterase 4 (PDE4) with moderate potency and imperfect drug-like properties. Toddacoumalone has the potential for the research of inflammatory diseases such as psoriasis.

GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b).

Xanthoquinodin A1 is an anticoccidial antibiotic having a new xanthone-anthraquinone conjugate system.

TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin treatment of the malaria parasitesPlasmodium falciparum .